INVERSE PROBABILITY OF CENSORING WEIGHTED ANALYSIS TO ADJUST THE TREATMENT EFFECT ON OVERALL SURVIVAL FOR SUBSEQUENT THERAPY: A CASE STUDY IN A CLINICAL TRIAL IN MULTIPLE MYELOMA

被引：0
|
作者：
Thilakarathne, P. [1 ]
Palumbo, A. [2 ]
Diels, J. [1 ]
Delforge, M. [3 ]
van Sanden, S. [4 ]
Mateos, M., V [5 ]
Chirita, O. [6 ]
Dimopoulos, M. A. [7 ]
van de Velde, H. [8 ]
San Miguel, J. F. [5 ]
机构：
[1] Janssen Pharmaceut NV, Beerse, Belgium
[2] Univ Turin, Turin, Italy
[3] Univ Hosp Leuven, Leuven, Belgium
[4] Janssen EMEA, EMEA HEMAR Analyt, Beerse, Belgium
[5] Hosp Univ Salamanca, Salamanca, Spain
[6] Janssen, High Wycombe, Bucks, England
[7] Alexandra Hosp, Athens, Greece
[8] Johnson & Johnson ORD, Beerse, Belgium
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.1770
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRM18
引用
收藏
页码：A546 / A546
页数：1
相关论文
共 39 条
  • [21] ASO Visual Abstract: Impact of Weekend Effect on Short- and Long-Term Survival of Patients Undergoing Esophagectomy for Cancer—A Population-Based, Inverse Probability of Treatment Weighted Analysis
    Tzu-Yi Yang
    Yu-Wen Wen
    Yin-Kai Chao
    Annals of Surgical Oncology, 2023, 30 : 3800 - 3801
  • [22] Pomalidomide, Daratumumab, and Dexamethasone After Lenalidomide Treatment in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): Final Overall Survival (OS) Analysis of the Phase II MM-014 Study
    Bahlis, Nizar J.
    Samaras, Christy
    Reece, Donna
    Sebag, Michael
    Matous, Jeffrey
    Berdeja, Jesus G.
    Shustik, Jesse
    Schiller, Gary J.
    Ganguly, Siddhartha
    Song, Kevin
    Seet, Christopher S.
    Acosta-Rivera, Mirelis
    Quick, Donald
    Anz, Bertrand
    Fonseca, Gustavo
    Liu, Hongjuan
    Gentili, Christian
    Siegel, David S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S494 - S495
  • [23] ASO Visual Abstract: Impact of Weekend Effect on Short- and Long-Term Survival of Patients Undergoing Esophagectomy for Cancer-A Population-Based, Inverse Probability of Treatment Weighted Analysis
    Yang, Tzu-Yi
    Wen, Yu-Wen
    Chao, Yin-Kai
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (06) : 3800 - 3801
  • [24] Clinical impact of probiotics on the efficacy of anti-PD-1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting
    Takada, Kazuki
    Shimokawa, Mototsugu
    Takamori, Shinkichi
    Shimamatsu, Shinichiro
    Hirai, Fumihiko
    Tagawa, Tetsuzo
    Okamoto, Tatsuro
    Hamatake, Motoharu
    Tsuchiya-Kawano, Yuko
    Otsubo, Kohei
    Inoue, Koji
    Yoneshima, Yasuto
    Tanaka, Kentaro
    Okamoto, Isamu
    Nakanishi, Yoichi
    Mori, Masaki
    INTERNATIONAL JOURNAL OF CANCER, 2021, 149 (02) : 473 - 482
  • [25] Overall Survival of Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone According to Prior Line of Therapy and Previous Exposure to Bortezomib: Secondary Analysis of the Phase 3 Endeavor Study
    Weisel, Katja C.
    Siegel, David
    San Miguel, Jesus F.
    Hajek, Roman
    Ho, P. Joy
    Gaidano, Gianluca
    Orlowski, Robert Z.
    Zhou, Lifen
    Kimball, Amy S.
    Moreau, Philippe
    BLOOD, 2017, 130
  • [26] Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial
    Falk, Ingrid Jakobsen
    Lund, Johan
    Green, Henrik
    Gruber, Astrid
    Alici, Evren
    Lauri, Birgitta
    Blimark, Cecilie
    Mellqvist, Ulf-Henrik
    Swedin, Agneta
    Forsberg, Karin
    Carlsson, Conny
    Hardling, Mats
    Ahlberg, Lucia
    Lotfi, Kourosh
    Nahi, Hareth
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (01) : 183 - 193
  • [27] Impact of treatment effect on measurable residual disease (MRD) and progression-free survival (PFS): an aggregate data analysis from randomized clinical trials in multiple myeloma (MM)
    Paiva, Bruno
    Zherniakova, Anastasiia
    Nunez, Jorge
    Rodriguez-Otero, Paula
    Shi, Qian
    Munshi, Nikhil
    Durie, Brian
    San-Miguel, Jesus
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S78 - S78
  • [28] Delay of initial radioactive iodine therapy beyond 3 months has no effect on clinical responses and overall survival in patients with thyroid carcinoma: A cohort study and a meta-analysis
    Cheng, Fang
    Xiao, Juan
    Huang, Fengyan
    Shao, Chunchun
    Ding, Shouluan
    Yun, Canhua
    Jia, Hongying
    CANCER MEDICINE, 2022, 11 (12): : 2386 - 2396
  • [29] Improved Survival for Multiple Myeloma in Denmark Based on Autologous Stem Cell Transplantation and Novel Drug Therapy in Collaborative Trials: Analysis of Accrual, Prognostic Variables, Selection Bias, and Clinical Behavior on Survival in More Than 1200 Patients in Trials of the Nordic Myeloma Study Group
    Johnsen, Hans E.
    Klausen, Tobias W.
    Boegsted, Martin
    Lenhoff, Stig
    Gimsing, Peter
    Christiansen, Ilse
    Gedde-Dahl, Tobias
    Lindas, Roald
    Mellqvist, Ulf-Henrik
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (04): : 290 - 296
  • [30] Overall and Progression Free Survival from the Mcrn-003/Myx.1 Trial: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma
    Venner, Christopher P.
    Leblanc, Richard
    Sandhu, Irwindeep
    White, Darrell J.
    Belch, Andrew
    Reece, Donna E.
    Chen, Christine I.
    Dolan, Sean
    Lalancette, Marc
    Louzada, Martha L.
    Kew, Andrea
    McCurdy, Arleigh
    Reiman, Tony
    Sherry, Max
    McDonald, Gail T.
    Monteith, Bethany Elaine
    Gul, Engin
    Chen, Bingshu E.
    Hay, Annette E.
    BLOOD, 2019, 134
1234